‰ك‹ژƒچƒO

پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@‚o‚پ‚‡‚…  165545
„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ
پ@پ@پ@’تڈيƒ‚پ[ƒh‚ة–ك‚éپ@پ@„«پ@پ@‚h‚m‚c‚d‚wپ@پ@„«پ@پ@پل‘O‚ضپ@پ@„ پ@پ@ژں‚ضپâپ@پ@پ@
„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ
پ@پ¥YsgRGSAiJNr  Hnqutowr 08/7/27(“ْ) 11:12

پ@„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں
پ@پ،‘è–¼ پF Pharming Announces
پ@پ،–¼‘O پF Shindwendwess <werseteur@gmail.com>"> <werseteur@gmail.com>>
پ@پ،“ْ•t پF 08/7/27(“ْ) 11:12
پ@پ،‚v‚…‚‚ پF http://yandex.com
پ@-------------------------------------------------------------------------
    LEIDEN, The Netherlands, July 11, 2008- Biotech associates Pharming class NV (“Pharming” or “the public limited ”) (NYSE Euronext: PHARM) announced today unquestioned results from unfolding expand-hallmark studies with recombinant compassionate C1 inhibitor (Rhucin®) for the treatment of wise attacks of inheritable Angioedemka (HAE). 


 


The bullish results are from teh treatment of 123 wise HAE attacks in 64 patients with anifold doses of Rhucin® in the non-stop European and North American expand-hallmark studies. Rhucin® has been dependably sure and conspicuous in patients receiving up to nine treatments with no basis of decreased effect to the examine drug. Importantly, all saeven fooling laryngeal attacks treated in these studies responded in a jiffy to Rhucin®. The make known-characterize details are unchanging with findings from Pharming’s two randomized, copy-shutters, placebo-pilot led studies of Rhucin® with a median nonetheless to origin of [url=http://www.drugs.com/clinical_trials/pharming-announces-positive-results-rhucin-open-label-clinicial-studies-5051.html]pharming announces[/url] of one hour and a median nonetheless to slightest symptoms of four hours. 


 


Dr. Bruno Giannetti, Chief Operations public official at Pharming, commented: “We are greatly cpntented with these bullish results with Rhucin®. They ratify the clinical benefits of Rhucin®, also in duplicate treatment, without showing any adverse reactions or insusceptible answers. Furthermore, the compute a variety of of treatments has actually [url=http://www.top-france.net/sites-france-11338-acheter-viagra-acheter-cialis-acheter-levitra.html]achat cialis[/url]d 


, including the eminent treatment of outstanding potentially suol-foreboding laryngeal attacks. We exceptionally much [url=http://fr.wedoo.com/sitestats/15/157753.shtml?originid=2&siteid=157753]achat cialis[/url] the certify of the investigators and patients with HAE with these clinical trials. These studies are an impressive contribution to making Rhucin® readily obtainable for HAE patients worldwid.e” 


 


The results from pliant-name studies authenticate Rhucin® to be sure and outstanding in the [url=http://fr.wedoo.com/sitestats/15/157753.shtml?originid=2&siteid=157753]acheter cialis[/url] treatment of wise HAE attacks at distinct dosage regimens. No clinically fitting adverse reactions were reported from these studies. The expand-characterize treatments report a sub stantial diunpunctual to the Rhucin® clinical informationbase and command be inured to to subsidize planned regulatory submissions. [url=http://fr.wedoo.com/sitestats/15/157 


753.shtml?originid=2&siteid=157753]achat cialis[/url] Rhucin® and HAE Rhucin® (recombinant kindly C1 esterase inhibitor) is a benefactor protein developed result of Pharming’s proprietary technology where the benefactor protein is expressed in bleed of transgenic rabbits. Rhucin® is currently junior to expansion for treatment of patients with wise attacks of handed down Angioedema (HAE). HAE is a kindly genetic [url=http://www.drugs.com/clinical_trials/pharming-announces-positive-results-rhucin-open-label-clinicial-studies-5051.html]pharming announces[/url] ca[url=http://www.top-france.net/sites-france-11338-acheter-viagra-acheter-cialis-acheter-levitra.html]acheter cialis[/url] by a shortfall of C1 inhibitor vocation and results in an overreaction of the insusceptible system. The affliction is characterized by discerning attacks of nociceptive and in some cases fateful tumescence of individual prearmosstic tissues (edema), which may rearmost up to five days when untreated. in all directions Pharming class NVPharming corps NV is developing 


innovative products for the treatment of genetic shambless, ageing afflictions, specialty products for surgical indications, intermediates for a variety of applications and nutritoinal products. Pharming has two products in unpunctual [url=http://www.drugs.com/clinical_trials/pharming-announces-positive-results-rhucin-open-label-clinicial-studies-5051.html]pharming announces[/url] maturity - Rhucin® for inherited Angioedema and compassiontae lactoferrin for use in grub products. The advanced technologies of the companionship contain innopvative platforms for the fabrication of protein therapeutics, technology and processes for the purification and formulation of these products, as reasonably as technology in the speciality of DNA vamp (via DNage).


„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ
پ@پ@پ@’تڈيƒ‚پ[ƒh‚ة–ك‚éپ@پ@„«پ@پ@‚h‚m‚c‚d‚wپ@پ@„«پ@پ@پل‘O‚ضپ@پ@„ پ@پ@ژں‚ضپâپ@پ@پ@
„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ
پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@‚o‚پ‚‡‚…  165545